A Phase 4 interventional study of Moxidectin 2 MG Oral Tablet and Placebo in Blepharitis, sponsored by Eye Research Foundation, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Eye Research Foundation, Inc. · Phase 4, Interventional, and Treatment
A Single-Center, Investigator-Masked, Randomized, Placebo-Controlled, Investigator Initiated Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation
73 studies on the registry are indexed under Blepharitis; 9 are open to participants now.
This study's enrollment of 24 is below the median of 60 across 65 interventional studies indexed under Blepharitis.
Browse Blepharitis studies →This is the only study on the registry with Eye Research Foundation, Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Active blepharitis with collarettes
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Moxidectin 2 MG Oral Tablet
Drug: Moxidectin 2 MG Oral Tablet · Drug: Placebo
Drug: Placebo
active medication
placebo pills
Collarette count
Collarette Count
Time frame: 6 weels
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxidectin